{"changes":[],"country":"GB","description":"Trimtech Therapeutics develops targeted protein degraders, branded TRIMTACs and TRIMGLUEs, that selectively remove disease-causing proteins to treat CNS and inflammatory disorders. It is built for patients with intractable disease driven by toxic protein buildup. Its programs use TRIM21, a widely expressed but underused ubiquitin ligase.","domain":"trimtech.bio","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":52.197585,"lng":0.139154,"location":"Cambridge, UK","name":"Trimtech Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":31000000,"currency":"USD","date":"2025-03-15","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"trimtech-bio","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"trimtech.bio","retrievedAt":"2026-05-08","status":"self-reported","url":"https://trimtech.bio"},{"fact":"description","publisher":"trimtech.bio","retrievedAt":"2026-05-08","status":"self-reported","url":"https://trimtech.bio"}],"stage":"seed","techStack":[],"totalRaisedUsd":31000000,"updatedAt":"2026-05-08"}